Notification That Annual Report Will Be Submitted Late (nt 10-k)

Date : 07/29/2019 @ 9:00PM
Source : Edgar (US Regulatory)
Stock : Pharmacyte Biotech, Inc. (QB) (PMCB)
Quote : 0.0473  0.0025 (5.58%) @ 9:00PM

Notification That Annual Report Will Be Submitted Late (nt 10-k)

 

    OMB APPROVAL
  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB Number: 3235-0058
  Expires: February 28, 2022
  Estimated average burden hours per response. 2.50

 

  FORM 12b-25 SEC FILE NUMBER
  333-68008
     
    CUSIP NUMBER
  NOTIFICATION OF LATE FILING 71715X104

 

(Check one): [X] Form 10-K           [_] Form 20-F           [_] Form 11-K           [_] Form 10-Q           [_] Form 10-D
[_] Form N-SAR       [_] Form N-CSR      [_] Form N-CEN
   
  For Period Ended: April 30, 2019                           
[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR
[_] Transition Report on Form N-CEN
 
For the Transition Period Ended: ____________________

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 
PharmaCyte Biotech, Inc.
Full Name of Registrant
 
 
Former Name if Applicable
 
23046 Avenida de la Carlota, Suite 600
Address of Principal Executive Office (Street and Number)
 
Laguna Hills, CA 92653
City, State and Zip Code

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

  [X]   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

 

  1  

 

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, N-CEN or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Registrant has experienced a delay in completing the necessary disclosures and finalizing its financial statements with its independent public accounting firm in connection with its Annual Report on Form 10-K for the period ended April 30, 2019 (“Annual Report”). As a result of this delay, the Registrant was unable to file the Annual Report by the prescribed filing date without unreasonable effort and expense.

 

PART IV — OTHER INFORMATION

           
(1) Name and telephone number of person to contact in regard to this notification
 
  Kenneth L. Waggoner   917   595-2850
  (Name)   (Area Code)   (Telephone Number)
 
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
  Yes  [X]     NO  [_]
 
   
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
  Yes  [_]     NO  [X]
 
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

PharmaCyte Biotech, Inc.

 

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:   July 29, 2019   By: /s/ Kenneth L. Waggoner
        Chief Executive Officer

 

PharmaCyte Biotech, Inc. (USOTC:PMCB)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more PharmaCyte Biotech, Inc. Charts.

PharmaCyte Biotech, Inc. (USOTC:PMCB)
Intraday Stock Chart

Today : Friday 13 December 2019

Click Here for more PharmaCyte Biotech, Inc. Charts.

Latest PMCB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.